HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.
Owens Corning For 4Q23 Expects Overall Performance To Result In Net Sales Slightly Below Last Year, While Generating Mid-Teen EBIT Margins
Fourth-Quarter 2023 Outlook
The key economic factors that impact the company's businesses are residential repair and remodeling activity, U.S. housing starts, global commercial construction activity, and
